116 results
Page 5 of 6
UPLOAD
sg2l8i wy8w07
23 Dec 20
Letter from SEC
12:00am
DRS
54jcgmqv2sbuz9o
18 Dec 20
Draft registration statement
12:00am
6-K
aig559wk drtw
17 Dec 20
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
6:15am
6-K
cubxidzufuv9li4
9 Dec 20
Current report (foreign)
4:23pm
6-K
8nfm6s6y6o46wa6 58in
9 Dec 20
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
6:30am
6-K
g1gobmmwapni5ld7
8 Dec 20
Amryt Announces $40m Private Placement with Leading Biotech Investors
6:05am
6-K
ta5rjj
5 Nov 20
Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
7:55am
6-K
32kud408wlx6ix
3 Nov 20
Current report (foreign)
8:45am
6-K
6m0ew2i bvr
29 Oct 20
Amryt Announces Positive Results from Phase 3 Trial of Filsuvez® In Epidermolysis Bullosa
8:00am
6-K
0xnihv6jhvzpa8fip
19 Oct 20
Current report (foreign)
8:00am
6-K
xqblur1v218j
15 Sep 20
Current report (foreign)
8:31am
6-K
n1wv85 fl5m3yda
9 Sep 20
Amryt Announces Positive Top Line Results from Pivotal Phase 3 “Ease” Trial of Filsuvez(r) In Epidermolysis Bullosa
8:23am
6-K
arkc3fh
11 Aug 20
Notification of Cancellation of Admission to Euronext Growth
10:04am
6-K
4b3ik9exdsb 100we
6 Aug 20
Amryt Announces Q2 2020 Results and Issues Positive Revenue Guidance for Fy 2020
9:43am
6-K
mjm3vh
10 Jul 20
Current report (foreign)
9:46am
S-8
EX-5.1
o8pht
8 Jul 20
Registration of securities for employees
5:24pm
S-8
5rfhnqbck gs6ej9zdu
8 Jul 20
Registration of securities for employees
5:24pm
424B4
700mzth
8 Jul 20
Prospectus supplement with pricing info
4:05pm
F-1/A
c2agsmdivc0mup6kk6
7 Jul 20
Registration statement (foreign) (amended)
5:02pm
F-1/A
EX-5.1
hza6zbb7b
7 Jul 20
Registration statement (foreign) (amended)
5:02pm